Loading clinical trials...
Loading clinical trials...
Expanded Access Treatment of Neladalkib (NVL-655) in Patients With Advanced ALK+ NSCLC or Other ALK+ Solid Tumors
Conditions
Interventions
NVL-655
Locations
43
United States
University Of California Irvine Medical Center
Orange, California, United States
University of Colorado Anschutz School of Medicine
Aurora, Colorado, United States
University of Chicago Medical Center
Chicago, Illinois, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Henry Ford Cancer Institute
Detroit, Michigan, United States
Last Updated
April 7, 2026
NCT05671510
NCT03340506
NCT07485114
NCT06066138
NCT05098132
NCT04977453
Lead Sponsor
Nuvalent Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions